Menaquinone-2

Menaquinone-2

SCHEMBL571905

CC(C)=CCCC(C)=CCC1=C(C)C(=O)c2ccccc2C1=O

nearest known ligand 0.97

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTGS1 P23219 4/20 0.97
MAPT P10636 3/20 0.97
PDE4A P27815 2/20 0.97
SNCA P37840 2/20 0.97
PDE3A Q14432 2/20 0.97
PGR P06401 1/20 0.97
HTR1A P08908 1/20 0.97
ADORA3 P0DMS8 1/20 0.97
MAPK1 P28482 1/20 0.97
DRD3 P35462 1/20 0.97
MAOB P27338 2/20 0.66
LMNA P02545 2/20 0.64
DHODH Q02127 2/20 0.52
ALOX5 P09917 8/20 0.51
ALDH1A1 P00352 2/20 0.50
CYP3A4 P08684 2/20 0.50
SMN1; SMN2 Q16637 2/20 0.50
KDM4E B2RXH2 2/20 0.50
MEN1 O00255 2/20 0.50
KMT2A Q03164 2/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Menaquinone-2 SCHEMBL29355593 1.00 PTGS1 (0.97) PTGS1MAPTPDE4ASNCAPDE3A
Menaquinone-2 SCHEMBL30606255 1.00 PTGS1 (0.97) PTGS1MAPTPDE4ASNCAPDE3A
Menaquinone-2 SCHEMBL416517 1.00 PTGS1 (0.97) PTGS1MAPTPDE4ASNCAPDE3A
SCHEMBL571907 0.99 PTGS1 (1.00) PTGS1MAPTPDE4ASNCAPDE3A
Menatetrenone SCHEMBL571912 0.99 PTGS1 (1.00) PTGS1MAPTPDE4ASNCAPDE3A
SCHEMBL8709976 0.99 PTGS1 (1.00) PTGS1MAPTPDE4ASNCAPDE3A
Menaquinone 7 SCHEMBL436068 0.99 PTGS1 (1.00) PTGS1MAPTPDE4ASNCAPDE3A
Menaquinone 6 SCHEMBL244452 0.99 PTGS1 (1.00) PTGS1MAPTPDE4ASNCAPDE3A
SCHEMBL14164356 0.99 PTGS1 (1.00) PTGS1MAPTPDE4ASNCAPDE3A
Menatetrenone SCHEMBL8703544 0.99 PTGS1 (1.00) PTGS1MAPTPDE4ASNCAPDE3A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20140031432-A1 TREATMENT OF MITOCHONDRIAL DISEASES WITH VITAMIN K AMPERE LIFE SCIENCES, INC. (US) 2014-01-30 US disclosed
EP-2601168-A1 TREATMENT OF MITOCHONDRIAL DISEASES WITH VITAMIN K Ampere Life Sciences, Inc. (US) 2013-06-12 EP disclosed
WO-2012170773-A1 ADJUNCTIVE THERAPY FOR THE TREATMENT OF MITOCHONDRIAL DISORDERS WITH QUINONES AND NAPHTHOQUINONES EDISON PHARMACEUTICALS, INC. (US) 2012-12-13 WO disclosed
WO-2012019032-A1 TREATMENT OF MITOCHONDRIAL DISEASES WITH VITAMIN K AMPERE LIFE SCIENCES, INC. (US) 2012-02-09 WO disclosed
EP-0872903-B1 Method for making hydrogen storage alloy powder and electrode comprising the alloy powder SHINETSU CHEMICAL CO (JP) 2001-10-04 EP disclosed
US-6277519-B1 QUENCHING AN ALLOY MELT; COMMINUTION SHIN-ETSU CHEMICAL CO., LTD. (JP) 2001-08-21 US disclosed
US-6096144-A TREATING WITH ACIDIC OR ALKALINE SOLUTION OF CONJUGATED UNSATURATED COMPOUND WITH AT LEAST 5 BONDS SHIN-ETSU CHEMICAL CO., LTD. (JP) 2000-08-01 US disclosed
US-5858571-A TREATING A PULVERIZED HYDROGEN ABSORBING ALLOY WITH A SOLUTION COMPRISING A CONJUGATED UNSATURATED COMPOUND SHIN-ETSU CHEMICAL CO., LTD. (JP) 1999-01-12 US disclosed
EP-0872903-A1 Method for making hydrogen storage alloy powder and electrode comprising the alloy powder Shin-Etsu Chemical Co., Ltd. (JP) 1998-10-21 EP disclosed
EP-0613877-B1 Preparation process of quinone derivative and intermediate for the preparation thereof EISAI KAGAKU KK (JP) 1998-05-20 EP disclosed
US-5608092-A INTERMEDIATES FOR VITAMIN K DERIVATIVES EISAI CHEMICAL CO., LTD. (JP) 1997-03-04 US disclosed
US-5476955-A Process for the preparation of a quinone derivative EISAI CHEMICAL CO., LTD. (JP) 1995-12-19 US disclosed
US-5412124-A Preparation process of naphthoquinone derivative and intermediate for the preparation thereof EISAI CHEMICAL CO., LTD. (JP) 1995-05-02 US disclosed
EP-0636598-A1 Preparation process of naphthoquinone derivatives and intermediates for the preparation thereof EISAI CHEMICAL CO., LTD. (JP) 1995-02-01 EP disclosed
EP-0613877-A1 Preparation process of quinone derivative and intermediate for the preparation thereof EISAI CHEMICAL CO., LTD. (JP) 1994-09-07 EP disclosed
EP-0172427-B1 PROCESS FOR PRODUCTION OF VINYL CHLORIDE POLYMER Shin-Etsu Chemical Co., Ltd. (JP) 1989-07-05 EP disclosed
US-4818441-A MEMBRANE STABILIZERS TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 1989-04-04 US disclosed
US-4758639-A Process for production of vinyl polymer SHIN-ETSU CHEMICAL CO., LTD. (JP) 1988-07-19 US disclosed
US-4757124-A Suspension or emulsion polymerizing vinyl chloride monomer or mixture of vinyl chloride with vinyl monomer copolymerizable therewith in reactor with walls coated with antiscaling compound containing dye or pigments SHIN-ETSU CHEMICAL CO., LTD. (JP) 1988-07-12 US disclosed
EP-0172427-A2 Process for production of vinyl chloride polymer Shin-Etsu Chemical Co., Ltd. (JP) 1986-02-26 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140031432-A1 TREATMENT OF MITOCHONDRIAL DISEASES WITH VITAMIN K FH, COQ8A, BCKDK PTGS1 2269/4885MAPT 1790/4885PDE4A 2847/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.